

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**RAJYA SABHA
UNSTARRED QUESTION NO.1389
TO BE ANSWERED ON 11TH MARCH, 2025**

REGULATION OF WEIGHT-LOSS DRUGS IN THE COUNTRY

1389: SHRI DEREK O' BRIEN:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether Government is aware of the proliferation of weight-loss drugs in the country;
- (b) if so, the details thereof including the data on the increase in consumption of these drugs over the last three years;
- (c) whether the current regulatory mechanisms in place take into account the problems being posed by the increase in consumption and overuse of weight-loss drugs in the country; and
- (d) if so, the details thereof and if not, the reasons therefor?

**ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND
FAMILY WELFARE
(SMT. ANUPRIYA PATEL)**

(a) to (d): Central Drugs Standard Control Organization (CDSCO) has approved the following three drugs for obesity/weight management in the country

- (i) Orlistat
- (ii) Tirzepatide
- (iii) Semaglutide

These drugs are required to be sold in accordance with provisions of Drugs and Cosmetics Act, 1940 & Rules 1945. Drugs should be used/consumed in accordance with recommendations for use.

Regulatory control over the sale and distribution of drugs is exercised through a system of licensing and inspection by State Licensing Authorities (SLAs) appointed by State Government. SLAs are empowered to take action in case of violation of regulatory provisions of Drugs and Cosmetics Act, 1940 & Rules 1945.
